Vestal Point Capital, LP — 13F Holdings & Portfolio
CIK 1974915 · latest 13F-HR filed 2026-05-15
Vestal Point Capital, LP manages $3.58B in 13F-reported U.S. long-equity assets across 90 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are RVMD (6.46%), BMRN (5.65%), ABVX (4.67%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 37 new positions, exited 22, added to 37, and trimmed 14.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$3.58B
Long-equity book
90
Distinct positions
2026-03-31
Filed 2026-05-15
+37 / −22 / ↑37 / ↓14
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Revolution Medicines Inc$207.5M +883.0%
- Repligen Corp$95.4M +701.3%
- Arrowhead Pharmaceuticals Inc$82.9M +138.7%
- Dyne Therapeutics Inc$70.2M +2989.6%
- Enliven Therapeutics Inc$68.4M +116.0%
Top Trims
- Terns Pharmaceuticals Inc-$129.1M -71.0%
- Abivax SA-$89.2M -34.8%
- Tyra Biosciences Inc-$61.7M -96.8%
- Globus Medical Inc-$58.7M -52.7%
- Olema Pharmaceuticals Inc-$34.9M -84.5%
New Positions
- Neurocrine Biosciences Inc$164.7M
- Sanofi SA$67.5M
- Boston Scientific Corp$50.2M
- Cogent Biosciences Inc$47.4M
- United Therapeutics Corp$44.5M
Exited Positions
- Arcellx Inc$190.7M
- Dexcom Inc$84.6M
- Merck & Co Inc$81.6M
- Abbott Laboratories$75.2M
- Jazz Pharmaceuticals PLC$49.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc | RVMD | 76155X100 | $231.0M | 6.46% | 2,375,000 | SH |
| 2 | BioMarin Pharmaceutical Inc | BMRN | 09061G101 | $202.0M | 5.65% | 3,575,000 | SH |
| 3 | Abivax SA | ABVX | 00370M103 | $167.0M | 4.67% | 1,500,000 | SH |
| 4 | Neurocrine Biosciences Inc | NBIX | 64125C109 | $164.7M | 4.60% | 1,250,000 | SH |
| 5 | Arrowhead Pharmaceuticals Inc | ARWR | 04280A100 | $142.6M | 3.99% | 2,275,000 | SH |
| 6 | Enliven Therapeutics Inc | ELVN | 29337E102 | $127.4M | 3.56% | 3,250,000 | SH |
| 7 | Repligen Corp | RGEN | 759916109 | $109.0M | 3.05% | 925,000 | SH |
| 8 | Bicara Therapeutics Inc | BCAX | 055477103 | $107.9M | 3.02% | 5,425,000 | SH |
| 9 | Nurix Therapeutics Inc | NRIX | 67080M103 | $100.8M | 2.82% | 6,500,000 | SH |
| 10 | Apogee Therapeutics Inc | APGE | 03770N101 | $92.6M | 2.59% | 1,100,000 | SH |
| 11 | Ascendis Pharma A/S | ASND | 04351P101 | $85.8M | 2.40% | 375,000 | SH |
| 12 | Immunocore Holdings PLC | IMCR | 45258D105 | $83.4M | 2.33% | 2,766,868 | SH |
| 13 | Taysha Gene Therapies Inc | TSHA | 877619106 | $80.5M | 2.25% | 18,000,000 | SH |
| 14 | Dyne Therapeutics Inc | DYN | 26818M108 | $72.5M | 2.03% | 4,000,000 | SH |
| 15 | Sanofi SA | SNY | 80105N105 | $67.5M | 1.89% | 1,400,000 | SH |
| 16 | BioCryst Pharmaceuticals Inc | BCRX | 09058V103 | $66.9M | 1.87% | 7,025,000 | SH |
| 17 | Scholar Rock Holding Corp | SRRK | 80706P103 | $65.1M | 1.82% | 1,324,422 | SH |
| 18 | Immatics NV | IMTX | N44445109 | $60.8M | 1.70% | 6,175,000 | SH |
| 19 | Bristol-Myers Squibb Co | BMY | 110122108 | $60.6M | 1.70% | 1,000,000 | SH |
| 20 | Alcon AG | ALC | H01301128 | $60.3M | 1.69% | 800,000 | SH |
| 21 | Monte Rosa Therapeutics Inc | GLUE | 61225M102 | $59.3M | 1.66% | 3,603,465 | SH |
| 22 | Vera Therapeutics Inc | VERA | 92337R101 | $55.0M | 1.54% | 1,368,159 | SH |
| 23 | Terns Pharmaceuticals Inc | TERN | 880881107 | $52.7M | 1.47% | 1,000,000 | SH |
| 24 | Globus Medical Inc | GMED | 379577208 | $52.6M | 1.47% | 610,520 | SH |
| 25 | Boston Scientific Corp | BSX | 101137107 | $50.2M | 1.40% | 800,000 | SH |
| 26 | Nuvalent Inc | NUVL | 670703107 | $49.4M | 1.38% | 481,715 | SH |
| 27 | Cogent Biosciences Inc | COGT | 19240Q201 | $47.4M | 1.32% | 1,230,888 | SH |
| 28 | Alto Neuroscience Inc | ANRO | 02157Q109 | $46.4M | 1.30% | 2,064,075 | SH |
| 29 | Rapport Therapeutics Inc | RAPP | 75383L102 | $44.9M | 1.26% | 1,436,229 | SH |
| 30 | Disc Medicine Inc | IRON | 254604101 | $44.8M | 1.25% | 700,000 | SH |
| 31 | United Therapeutics Corp | UTHR | 91307C102 | $44.5M | 1.24% | 75,000 | SH |
| 32 | Celldex Therapeutics Inc | CLDX | 15117B202 | $38.8M | 1.09% | 1,224,165 | SH |
| 33 | KalVista Pharmaceuticals Inc | KALV | 483497103 | $37.2M | 1.04% | 1,850,000 | SH |
| 34 | Xenon Pharmaceuticals Inc | XENE | 98420N105 | $37.2M | 1.04% | 639,900 | SH |
| 35 | Solid Biosciences Inc | SLDB | 83422E204 | $36.0M | 1.01% | 5,000,000 | SH |
| 36 | Bright Minds Biosciences Inc | DRUG | 10919W405 | $35.9M | 1.00% | 492,319 | SH |
| 37 | Protagonist Therapeutics Inc | PTGX | 74366E102 | $34.4M | 0.96% | 326,159 | SH |
| 38 | Denali Therapeutics Inc | DNLI | 24823R105 | $34.0M | 0.95% | 1,773,326 | SH |
| 39 | Regeneron Pharmaceuticals Inc | REGN | 75886F107 | $30.9M | 0.86% | 40,000 | SH |
| 40 | Waters Corp | WAT | 941848103 | $29.8M | 0.83% | 100,000 | SH |
| 41 | Viking Therapeutics Inc | VKTX | 92686J106 | $29.7M | 0.83% | 914,147 | SH |
| 42 | Inspire Medical Systems Inc | INSP | 457730109 | $27.8M | 0.78% | 539,269 | SH |
| 43 | Crescent Biopharma Inc | CBIO | G2545C104 | $27.6M | 0.77% | 1,500,000 | SH |
| 44 | Trevi Therapeutics Inc | TRVI | 89532M101 | $25.8M | 0.72% | 2,166,504 | SH |
| 45 | Lexeo Therapeutics Inc | LXEO | 52886X107 | $25.7M | 0.72% | 4,475,000 | SH |
| 46 | Soleno Therapeutics Inc | SLNO | 834203309 | $24.4M | 0.68% | 730,000 | SH |
| 47 | Beta Bionics Inc | BBNX | 08659B102 | $22.2M | 0.62% | 2,211,518 | SH |
| 48 | Nektar Therapeutics | NKTR | 640268306 | $20.5M | 0.57% | 285,000 | SH |
| 49 | Cytokinetics Inc | CYTK | 23282W605 | $19.8M | 0.55% | 300,000 | SH |
| 50 | AstraZeneca PLC | AZN | G0593M107 | $19.7M | 0.55% | 100,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $3.58B | 90 | 0001974915-26-000004 |
| 2025-12-31 | 2026-02-17 | $2.94B | 76 | 0001974915-26-000002 |
| 2025-09-30 | 2025-11-14 | $2.21B | 81 | 0001974915-25-000008 |